{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T17:17:30Z","timestamp":1790097450369,"version":"4.0.1"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["ejinme.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.ejim.2017.05.002","type":"journal-article","created":{"date-parts":[[2017,5,10]],"date-time":"2017-05-10T03:02:33Z","timestamp":1494385353000},"page":"89-95","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Mortality in dialysis patients with cinacalcet use: A large observational registry study"],"prefix":"10.1016","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8479-5207","authenticated-orcid":false,"given":"Claudia","family":"Friedl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilbert","family":"Reibnegger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9832-1026","authenticated-orcid":false,"given":"Reinhard","family":"Kramar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6944-6041","authenticated-orcid":false,"given":"Emanuel","family":"Zitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Pilz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes F.E.","family":"Mann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander R.","family":"Rosenkranz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2017.05.002_bb0005","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1161\/01.CIR.0000095676.90936.80","article-title":"Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention","volume":"108","author":"Sarnak","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2017.05.002_bb0010","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1097\/01.ASN.0000133041.27682.A2","article-title":"Mineral metabolism, mortality, and morbidity in maintenance hemodialysis","volume":"15","author":"Block","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ejim.2017.05.002_bb0015","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1093\/ndt\/gfq219","article-title":"Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population","volume":"26","author":"Floege","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ejim.2017.05.002_bb0020","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/sj.ki.5001514","article-title":"Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients","volume":"70","author":"Kalantar-Zadeh","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.ejim.2017.05.002_bb0025","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1056\/NEJMoa031633","article-title":"Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis","volume":"350","author":"Block","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2017.05.002_bb0030","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.2215\/CJN.01040308","article-title":"Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results","volume":"3","author":"Fishbane","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ejim.2017.05.002_bb0035","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1681\/ASN.2004060512","article-title":"Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study","volume":"16","author":"Lindberg","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ejim.2017.05.002_bb0040","doi-asserted-by":"crossref","first-page":"36","DOI":"10.2215\/CJN.03591006","article-title":"The OPTIMA study: assessing a new cinacalcet (Sensipar\/Mimpara) treatment algorithm for secondary hyperparathyroidism","volume":"3","author":"Messa","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ejim.2017.05.002_bb0045","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/j.1523-1755.2005.67139.x","article-title":"Achieving NKF-K\/DOQI bone metabolism and disease treatment goals with cinacalcet HCl","volume":"67","author":"Moe","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.ejim.2017.05.002_bb0050","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1093\/ndt\/gfp144","article-title":"Cinacalcet and achievement of the NKF\/K-DOQI recommended target values for bone and mineral metabolism in real-world clinical practice\u2014the ECHO observational study","volume":"24","author":"Urena","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ejim.2017.05.002_bb0055","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s00508-010-1515-x","article-title":"Effective use of cinacalcet for the treatment of secondary hyperparathyroidism in Austrian dialysis patients\u2014results of the Austrian cohort of the ECHO study","volume":"123","author":"Zitt","year":"2011","journal-title":"Wien Klin Wochenschr"},{"key":"10.1016\/j.ejim.2017.05.002_bb0060","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/ki.2010.167","article-title":"Cinacalcet hydrochloride treatment significantly improves all-cause and cardiovascular survival in a large cohort of hemodialysis patients","volume":"78","author":"Block","year":"2010","journal-title":"Kidney Int"},{"key":"10.1016\/j.ejim.2017.05.002_bb0065","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMoa1205624","article-title":"Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis","volume":"367","author":"Investigators","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2017.05.002_bb0070","article-title":"What can we learn from a statistically inconclusive trial? Consensus conference on the EVOLVE study results","volume":"30","author":"Locatelli","year":"2013","journal-title":"G Ital Nefrol"},{"key":"10.1016\/j.ejim.2017.05.002_bb0075","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1097\/MNH.0b013e328365b3a3","article-title":"What have we learned about chronic kidney disease-mineral bone disorder from the EVOLVE and PRIMO trials?","volume":"22","author":"Moe","year":"2013","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.ejim.2017.05.002_bb0080","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1161\/CIRCULATIONAHA.114.013876","article-title":"Cinacalcet, fibroblast growth factor-23, and cardiovascular disease in hemodialysis: the evaluation of Cinacalcet HCl therapy to lower cardiovascular events (EVOLVE) trial","volume":"132","author":"Moe","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2017.05.002_bb0085","unstructured":"Kramar R. Austrian dialysis and transplant registry (OEDTR). Annual Report 2015, 2015 http:\/\/www.nephro.at\/oedtr.htm (08 May 2017, date last accessed)."},{"key":"10.1016\/j.ejim.2017.05.002_bb0090","first-page":"S1","article-title":"KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD)","volume":"113","author":"Kidney Disease: Improving Global Outcomes CKDMBDWG","year":"2009","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.ejim.2017.05.002_bb0095","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S0272-6386(03)00905-3","article-title":"K\/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease","volume":"42","author":"National Kidney F","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ejim.2017.05.002_bb0100","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/ki.2008.60","article-title":"Adynamic bone in patients with chronic kidney disease","volume":"73","author":"Andress","year":"2008","journal-title":"Kidney Int"},{"key":"10.1016\/j.ejim.2017.05.002_bb0105","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2215\/CJN.00870805","article-title":"Cinacalcet hydrochloride (Sensipar) in hemodialysis patients on active vitamin D derivatives with controlled PTH and elevated calcium\u00d7phosphate","volume":"1","author":"Chertow","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ejim.2017.05.002_bb0110","first-page":"i29","article-title":"Clinical outcomes in secondary hyperparathyroidism and the potential role of calcimimetics","volume":"1","author":"Cunningham","year":"2008","journal-title":"NDT Plus"},{"key":"10.1016\/j.ejim.2017.05.002_bb0115","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2215\/CJN.01760215","article-title":"Clinical and practical use of Calcimimetics in dialysis patients with secondary hyperparathyroidism","volume":"11","author":"Bover","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ejim.2017.05.002_bb0120","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1093\/ndt\/gfq725","article-title":"The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis","volume":"26","author":"Raggi","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ejim.2017.05.002_bb0125","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1056\/NEJMe1212368","article-title":"Trials in kidney disease\u2014time to EVOLVE","volume":"367","author":"Perkovic","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2017.05.002_bb0130","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.114.001363","article-title":"Effects of cinacalcet on atherosclerotic and nonatherosclerotic cardiovascular events in patients receiving hemodialysis: the EValuation of cinacalcet HCl therapy to lower CardioVascular events (EVOLVE) trial","volume":"3","author":"Wheeler","year":"2014","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ejim.2017.05.002_bb0135","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1291\/hypres.27.47","article-title":"Left ventricular hypertrophy is associated with arterial stiffness and vascular calcification in hemodialysis patients","volume":"27","author":"Nitta","year":"2004","journal-title":"Hypertens Res"},{"key":"10.1016\/j.ejim.2017.05.002_bb0140","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1172\/JCI46122","article-title":"FGF23 induces left ventricular hypertrophy","volume":"121","author":"Faul","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ejim.2017.05.002_bb0145","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.cmet.2015.09.002","article-title":"Activation of cardiac fibroblast growth factor receptor 4 causes left ventricular hypertrophy","volume":"22","author":"Grabner","year":"2015","journal-title":"Cell Metab"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620517301784?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620517301784?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T21:23:01Z","timestamp":1535836981000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620517301784"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":29,"alternative-id":["S0953620517301784"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2017.05.002","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mortality in dialysis patients with cinacalcet use: A large observational registry study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2017.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}